Citation

Campagne DM. MedGenMed 2005; 7(3): 22.

Affiliation

Department of Personality, Evaluation and Psychological Treatments, Universidad Nacional de Educacion a Distancia, Faculty of Psychology, Madrid, Spain. danplaton@hotmail.com

Copyright

(Copyright © 2005, Medscape)

DOI

unavailable

PMID

16369248

PMCID

PMC1681629

Abstract

Venlafaxine is a widely used serotonin- and norepinephrine-reuptake inhibitor-type antidepressant that causes serious adverse effects in at least 5% of cases. Serious withdrawal symptoms may occur within hours of cessation or reduction of the usual dosage and may affect motor and coordination skills to such a degree that patients should be explicitly urged either to adhere to a strict medication routine or not to drive a car. Recent clinical evidence about withdrawal symptoms is presented that may indicate incidents in noradrenergic activity irrespective of dosage.

Language: en